Research programme: aldosterone synthase inhibitors - ElexoPharm/Merck

Drug Profile

Research programme: aldosterone synthase inhibitors - ElexoPharm/Merck

Alternative Names: Aldosterone synthase cytochrome P-450 inhibitors; CYP11B2 inhibitors - ElexoPharm; Cytochrome P-450 CYP11B2 inhibitors - ElexoPharm

Latest Information Update: 04 Jul 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator ElexoPharm GmbH
  • Developer Angion Biomedica; ElexoPharm GmbH; Merck & Co
  • Class Cardiovascular therapies
  • Mechanism of Action Aldosterone synthase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Cardiovascular disorders
  • Research Kidney disorders

Most Recent Events

  • 22 Jun 2017 Early research in Kidney disorders in USA (unspecified route)
  • 22 Jun 2017 Angion Biomedica in-licensed aldosterone synthase inhibitors from ElexoPharm GmbH for the treatment of chronic kidney disease
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top